Acompany that manages to invent the first drug to restore vision in people going blind from a disease of aging would, under ordinary circumstances, expect a panoply of rewards: hosannas from medical ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

One of the many concerns about President Obama’s health care legislation is that it will encourage — if not eventually require — the government to approve the cheapest rather than the best medical ...

LONDON, March 4 (Reuters) - Britain's health cost watchdog has rejected eye drug Lucentis as a treatment for diabetic macular oedema, fuelling further controversy over the pricey medicine, which is ...

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

LONDON, Jan 4 (Reuters) - Britain's healthcare cost watchdog has given its backing to eye drug Lucentis t o treat diabetes-related problems after Swiss drugmaker Novartis offered it at a discount to ...

Novartis and Roche have been fined a collective $528 million by France’s anti-trust regulator for allegedly conspiring to promote the expensive eye disease treatment Lucentis over a less pricey drug, ...

As expected, the FDA on Friday gave its approval to Genentech to market Lucentis for wet, age-related macular degeneration. Genentech says it plans to charge $1,950 a dose for the drug, which will go ...

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023. On day ...

Novartis announces the launch in Europe of the Lucentis pre-filled syringe (PFS), which is specifically designed for intraocular injection The Lucentis PFS can lead to improved patient treatment via a ...

Lucentis is the first anti-VEGF therapy approved for diabetic macular edema (DME) in Japan Pivotal clinical data in Asian patients show a significant increase in mean visual acuity following treatment ...